Pfizer Inc. (PFE)

35.09
0.22 0.63
NYSE : Health Technology
Prev Close 34.87
Open 34.96
Day Low/High 34.80 / 35.23
52 Wk Low/High 33.97 / 46.47
Volume 16.00M
Avg Volume 24.93M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 191.43B
EPS 1.90
P/E Ratio 15.59
Div & Yield 1.44 (3.98%)
Jim Cramer: It's Looking Like the 1980s

Jim Cramer: It's Looking Like the 1980s

Kimberly-Clark's performance is nothing to sneeze at, and neither is Coca-Cola's, as higher sales, higher prices and big demand from emerging markets appear to give us a return to the good old days of great senior growth stocks.

FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), For Certain Cancers And Autoimmune Conditions

FDA Approves Pfizer's Biosimilar, RUXIENCE™ (rituximab-pvvr), For Certain Cancers And Autoimmune Conditions

Pfizer Inc. (NYSE:PFE) today announced the United States (U.

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

Dow, S&P 500 Post Record Closes on Rate Cut Hopes, Healthcare Rally

The Dow & S&P 500 closed at record highs with the S&P barely missing ending the day above 3,000.

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

AstraZeneca Biopharma President Talks Drug Rebates, Pricing

Is pharma feeling the pressure now that PBM stocks are released from regulatory risk?

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo Shares Soar as Hemophilia Drug Shows Promise

Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo And Pfizer Announce Updated Phase 1/2 Results For SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks End Lower; Jobs Rebound Trims Hope of Fed Rate Cut

Stocks fell Friday as a surprising rebound in June hiring reduced the likelihood of an interest rate cut by the Federal Reserve.

Watch These 4 Japanese Drugmakers With Big Coming Events

Watch These 4 Japanese Drugmakers With Big Coming Events

Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

Sen. Elizabeth Warren Urges New Pfizer Board Member Gottlieb to Resign

Sen. Elizabeth Warren Urges New Pfizer Board Member Gottlieb to Resign

The Senator says that Gottlieb's appointment to the company's board smacks of the Washington revolving door that has become prevalent.

Pfizer Completes Acquisition Of Therachon

Pfizer Completes Acquisition Of Therachon

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.

Pfizer Gains on Positive Children-Dermatitis Treatment Results

Pfizer Gains on Positive Children-Dermatitis Treatment Results

Shares of Pfizer rise after the company announces positive results in a late-stage, non-steroid trial of a treatment for chronic dermatitis, or eczema, in kids.

3 Autopilot Funds for a High-Yield Portfolio

3 Autopilot Funds for a High-Yield Portfolio

This portfolio is built to hold up in any market, throw off a steady 8% dividend and pay monthly dividends, to boot.

Pfizer Announces Results From Phase 3 Trial Of Revatio® (Sildenafil Citrate) In Newborns With Persistent Pulmonary Hypertension

Pfizer Announces Results From Phase 3 Trial Of Revatio® (Sildenafil Citrate) In Newborns With Persistent Pulmonary Hypertension

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the efficacy and safety of intravenous (IV) sildenafil when added to inhaled nitric oxide (iNO) for the treatment of newborns with Persistent Pulmonary Hypertension (PPHN) did not meet...

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems

An analyst at Baird says a Pfizer gene therapy drug had safety and efficacy issues during a study.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Pfizer Presents Initial Clinical Data On Phase 1b Gene Therapy Study For Duchenne Muscular Dystrophy (DMD)

Pfizer Presents Initial Clinical Data On Phase 1b Gene Therapy Study For Duchenne Muscular Dystrophy (DMD)

Pfizer Inc. (NYSE:PFE) will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy (DMD) at the 25th Annual Parent Project Muscular Dystrophy (PPMD) Connect Conference in...

Pfizer Receives U.S. FDA Approval For Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

Pfizer Receives U.S. FDA Approval For Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

Pfizer Inc. (NYSE:PFE) today announced the United States (U.

Scott Gottlieb Elected To Pfizer's Board Of Directors

Scott Gottlieb Elected To Pfizer's Board Of Directors

Pfizer Inc. (NYSE:PFE) today announced the election of Dr.

Pfizer Declares Third-Quarter 2019 Dividend

Pfizer Declares Third-Quarter 2019 Dividend

The Board of Directors of Pfizer Inc. today declared a 36-cent third-quarter 2019 dividend on the company's common stock, payable September 3, 2019, to holders of the Common Stock of record at the close of business on August 2, 2019.

Using Technical Analysis: Cramer's 'Mad Money' Recap (Wednesday 6/26/19)

Using Technical Analysis: Cramer's 'Mad Money' Recap (Wednesday 6/26/19)

Jim Cramer explains the art and science of technical analysis.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

European Commission Approves TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

European Commission Approves TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) today announced that the European Commission approved TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer susceptibility...

A Handful of Small Biotechs That Make for Merger Chatter

A Handful of Small Biotechs That Make for Merger Chatter

The names include a veterinary drug concern plus companies with successful drugs on the market.

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

NEW YORK, June 18, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed...

TheStreet Quant Rating: B (Buy)